Enhanced Combination Therapy for Coronavirus Infections

The present invention relates to improved methods and systems for treating and preventing coronavirus infections through a combination of anti-viral drugs and vaccines, addressing limitations of existing treatments by reducing vaccine breakthrough infections, enhancing vaccine efficacy, and minimizing adverse effects.

The original patent disclosed methods for treating coronavirus infections using a combination of antibiotics, anti-viral drugs, and vaccines. However, these methods had limitations, including the potential for vaccine breakthrough infections, reduced vaccine efficacy, and adverse effects. The present invention addresses these limitations by introducing novel formulations, dosing regimens, and monitoring systems to improve treatment outcomes.

The inventive concept comprises methods and systems for treating and preventing coronavirus infections using a combination of anti-viral drugs and vaccines. In one embodiment, an anti-viral drug combination is formulated to prevent in vivo mutations of the causative agent, reducing the likelihood of vaccine breakthrough infections. In another embodiment, a system for treating coronavirus infections includes an antibiotic and/or anti-viral drug, a vaccine directed to a coronavirus, and a means for monitoring and adjusting the dosage of the antibiotic and/or anti-viral drug based on the individual's immune response. The inventive concept also includes methods for enhancing the efficacy of a vaccine against a coronavirus infection by administering an anti-viral drug combination to prevent replication of newly-inhaled mutants in the already vaccinated individual.

The present invention's novelty lies in its ability to prevent vaccine breakthrough infections, enhance vaccine efficacy, and minimize adverse effects through the use of novel formulations, dosing regimens, and monitoring systems. The inventive step is the recognition that a combination of anti-viral drugs and vaccines, when formulated and dosed in a specific manner, can address the limitations of existing treatments and provide improved treatment outcomes.

Alternative embodiments of the inventive concept may include different formulations of the anti-viral drug combination, varying dosing regimens, and alternative monitoring systems. Variations may also include the use of different vaccines or anti-viral drugs, or the incorporation of additional therapeutic agents to enhance treatment outcomes.

The present invention has significant commercial potential in the treatment and prevention of coronavirus infections, with a target market including pharmaceutical companies, healthcare providers, and government agencies. The inventive concept's ability to reduce vaccine breakthrough infections, enhance vaccine efficacy, and minimize adverse effects makes it an attractive solution for addressing the ongoing pandemic and future coronavirus outbreaks.